The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
1 to 10 of 2222    Next 10 >    Last >>
Add to Report ID Question Status Last Updated
20200059

Reportability--Kidney:  Is Bosniak 4 cystic lesion of right kidney reportable, and would the first CT date be the date of diagnosis?  See Discussion.

Final Oct 29 2020
20200058

Surgery of Primary Site/Surgery Codes, NOS--Pancreas:  What exactly is an extended pancreatoduodenectomy? Must the entire pancreas be resected in order to use code 70? What minimal requirements must be met to use code 70? How should a Whipple with cholecystectomy, partial omentectomy, common hepatic excision, portal vein resection, and lymphadenectomy be coded?

Final Oct 29 2020
20200057

Histology--Lung:  Is there a better code for SMARCA4-deficient malignant neoplasms than 8000/3 that could be used especially given its aggressive nature? This term is not included in the Lung Solid Tumor Rules or ICD-O-3.1 and 3.2.  See Discussion.

Final Oct 29 2020
20200056

Reportability--Gallbladder:  Is Intracholecystic papillary neoplasm (ICPN) with low-grade intraepithelial neoplasia reportable? The primary site is gallbladder.

Final Oct 29 2020
20200054

Solid Tumor Rules (2018)/Multiple primaries--Liver: When does a hepatocellular carcinoma (HCC) recurrence in the same area of the liver get accessioned as a new tumor following TACE/Y90/RFA? If there is a new HCC in the same area as previously treated but it is stated to be recurrent and/or progressive disease, is that evidence of a disease-free interval? If the tumor area is stated to be LR-TR and non-viable, but then a new HCC in that area is diagnosed, does that count as a disease-free interval? See Discussion.

Final Oct 15 2020
20200053

Solid Tumor Rules (2018)/Multiple primaries--Bladder. Would the metastatic diagnosis indicate a new primary?  If the metastatic diagnosis indicates a new primary, would the primary site be C688 and date of diagnosis 11/14/18? See Discussion.

Final Oct 15 2020
20200052

Solid Tumor Rules (2018)/Histology--Prostate: How is the histology coded for a diagnosis of mixed prostatic adenocarcinoma (5%) and small cell neuroendocrine carcinoma (95%) from a transurethral resection of the prostate? See Discussion.

 

Final Oct 13 2020
20200051

Primary site/Unknown and ill-defined site--Melanoma:  What is the primary site for a case of metastatic melanoma with an unknown primary site? See Discussion.

Final Oct 02 2020
20200050

Surgery of Primary Site/Multiple primaries--Breast: Should the Surgery of Primary Site for the 2020 diagnosis be coded 51 (Modified radical mastectomy without removal of uninvolved contralateral breast) when a partial mastectomy and axillary lymph node dissection are performed for a 2011 right breast primary and a subsequent 2020 right breast primary is treated with a total mastectomy only? See Discussion.
 

Final Oct 02 2020
20200049

Summary Stage 2018/EOD 2018--Lymphoma Orbital Adnexa:  What is the correct Summary Stage 2018 (SS2018) for the site/histology Orbit, NOS (C696), 9699/3?  In SEER*RSA, Extent of Disease (EOD) Primary Tumor references code 7 (Distant), whereas SS2018 assigns code 2 (Regional)?  See Discussion.

Final Sep 28 2020
Next 10 >